Drugs
-
OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) Information
To report any unexpected adverse or serious events associated with the use of these products, please contact the FDA MedWatch program using the information at the bottom of this page.
-
Related Information
FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed
8/3/2009Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc)
Issued 8/3/2009Update of Safety Review of OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc)
Issued 8/3/2009FDA Requires Boxed Warning for All Botulinum Toxin Products
FDA news release (4/30/2009)Follow-up to the February 8, 2008, Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)
Issued 4/2009Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) [ARCHIVED]
Issued 2/2008
-
-
Additional Resources
FDA approves Botox to treat overactive bladder
FDA news release (1/18/2013)FDA approves Botox to treat specific form of urinary incontinence
FDA news release (8/25/2011)FDA approves Botox to treat chronic migraine
FDA news release (10/15/2010)
-
-
-
